Short Interest in Franklin Genomic Advancements ETF (BATS:HELX) Declines By 74.2%

Posted by Latisha Jones on Jul 26th, 2026

Franklin Genomic Advancements ETF (BATS:HELX – Get Free Report) saw a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 4,118 shares, a drop of 74.2% from the June 30th total of 15,981 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average daily volume of 3,276 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. LPL Financial LLC boosted its holdings in shares of Franklin Genomic Advancements ETF by 22.4% in the fourth quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock valued at $404,000 after buying an additional 2,037 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Franklin Genomic Advancements ETF by 19.1% during the second quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock worth $87,000 after acquiring an additional 502 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Franklin Genomic Advancements ETF during the second quarter worth $42,000. Finally, Kestra Advisory Services LLC bought a new stake in Franklin Genomic Advancements ETF in the 4th quarter valued at $39,000.

Franklin Genomic Advancements ETF Price Performance

BATS:HELX opened at $38.85 on Friday. Franklin Genomic Advancements ETF has a fifty-two week low of $27.54 and a fifty-two week high of $41.30. The stock has a market capitalization of $15.54 million, a PE ratio of 26.71 and a beta of 1.05. The business’s 50-day simple moving average is $37.20 and its 200-day simple moving average is $35.44.

Franklin Genomic Advancements ETF Company Profile

(Get Free Report)

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.